Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs

Abstract The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n = 20), HIV/HCV-co-infected (n = 66) patients and healthy control...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mercedes Márquez-Coello, Ana Arizcorreta, María Rodríguez-Pardo, Francisco Illanes-Álvarez, Denisse Márquez, Sara Cuesta-Sancho, José-Antonio Girón-González
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cfe9d9450e2a40d7a8bdb638aba668a4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cfe9d9450e2a40d7a8bdb638aba668a4
record_format	dspace
spelling	oai:doaj.org-article:cfe9d9450e2a40d7a8bdb638aba668a42021-12-02T16:57:37ZModifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs10.1038/s41598-021-89370-62045-2322https://doaj.org/article/cfe9d9450e2a40d7a8bdb638aba668a42021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89370-6https://doaj.org/toc/2045-2322Abstract The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n = 20), HIV/HCV-co-infected (n = 66) patients and healthy controls (n = 15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-β1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of ≤ 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-β1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS > 9.5 achieved a M12 LS ≤ 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS > 9.5 achieved a LS under this cutoff point.Mercedes Márquez-CoelloAna ArizcorretaMaría Rodríguez-PardoFrancisco Illanes-ÁlvarezDenisse MárquezSara Cuesta-SanchoJosé-Antonio Girón-GonzálezNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mercedes Márquez-Coello Ana Arizcorreta María Rodríguez-Pardo Francisco Illanes-Álvarez Denisse Márquez Sara Cuesta-Sancho José-Antonio Girón-González Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
description	Abstract The objective of this work was to identify predictive factors of fibrosis regression after direct antiviral agents (DAAs) in HCV-monoinfected and HIV/HCV-coinfected patients. This was a prospective study of HCV-monoinfected (n = 20), HIV/HCV-co-infected (n = 66) patients and healthy controls (n = 15). Patients had started DAAs and achieved sustained virological response. Liver stiffness (LS) and serum concentrations of profibrotic transforming growth factor (TGF)-β1 and CXC chemokine ligand 4 (CXCL4) and antifibrotic HGF hepatocyte growth factor (HGF) were analyzed at baseline (M0) and 12 months after starting DAAs (M12). A M12 LS achievement of ≤ 9.5 kPa was considered the cutoff point to discharge from a liver clinic. The LS decrease from M0 to M12 was 34%. No significant differences were observed in LS decline between HCV- and HIV/HCV-infected individuals. Changes of serum CXCL4, TGF-β1 and HGF levels did not correlate with LS improvement. 16 out from 56 patients (28%) with a baseline LS > 9.5 achieved a M12 LS ≤ 9.5. HCV-monoinfected and HIV/HCV coinfected patients experienced a significant reduction of LS after sustained virological response. This improvement did not correlate with changes in serum profibrotic or antifibrotic markers. A 29% of those with a baseline LS > 9.5 achieved a LS under this cutoff point.
format	article
author	Mercedes Márquez-Coello Ana Arizcorreta María Rodríguez-Pardo Francisco Illanes-Álvarez Denisse Márquez Sara Cuesta-Sancho José-Antonio Girón-González
author_facet	Mercedes Márquez-Coello Ana Arizcorreta María Rodríguez-Pardo Francisco Illanes-Álvarez Denisse Márquez Sara Cuesta-Sancho José-Antonio Girón-González
author_sort	Mercedes Márquez-Coello
title	Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_short	Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_full	Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_fullStr	Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_full_unstemmed	Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
title_sort	modifications of liver stiffness and cxcl4, tgf-β1 and hgf are similar in hcv- and hiv/hcv-infected patients after daas
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cfe9d9450e2a40d7a8bdb638aba668a4
work_keys_str_mv	AT mercedesmarquezcoello modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas AT anaarizcorreta modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas AT mariarodriguezpardo modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas AT franciscoillanesalvarez modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas AT denissemarquez modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas AT saracuestasancho modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas AT joseantoniogirongonzalez modificationsofliverstiffnessandcxcl4tgfb1andhgfaresimilarinhcvandhivhcvinfectedpatientsafterdaas
_version_	1718382530560786432

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs

Ejemplares similares